Results 41 to 50 of about 100,425 (314)
Journal of the Royal Society of Medicine, 1989 Mesothelioma is a malignant tumour of the pleura or peritoneum caused by asbestos. It is increasing in frequency and the prognosis remains grim, with average survival around 1 year.Medical literature and personal experience.Amphibole fibres are far more potent than chrysotile in causing mesothelioma.A minority view suggests that mesotheliomas in those ...
openaire +4 more sources
Biomarkers in mesothelioma [PDF]
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2017 Mesothelioma is an aggressive cancer of pleural and peritoneal cells that is difficult to diagnose and monitor. Numerous studies have attempted to identify a blood- or pleural fluid-based biomarker that could be used in the diagnostic pathway. More recently, there has been interest in the ability of serum/plasma biomarkers to monitor mesothelioma ...
Arnold, David T, Maskell, Nick A
openaire +5 more sources
Gastroenterology Research and Practice, 2016 Malignant peritoneal mesothelioma with invasion of the liver is an invariably fatal disease. We aimed to clarify the characteristics of malignant peritoneal mesothelioma cases with liver involvement. The clinical presentation, computed tomography images,
Shan-shan Su +7 more
doaj +1 more source
Tumors that Mimic Asbestos-Related Mesothelioma: Time to Consider a Genetics-Based Tumor Registry?
Frontiers in Genetics, 2014 The diagnosis of mesothelioma is not always straightforward, despite known immunohistochemical markers and other diagnostic techniques. One reason for the difficulty is that extrapleural tumors resembling mesothelioma may have several possible ...
Brent Daniel Kerger +2 more
doaj +1 more source
Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells
Cell Death and Disease, 2023 Mesothelioma is an aggressive cancer of the mesothelial layer associated with an extensive fibrotic response. The latter is in large part mediated by cancer-associated fibroblasts which mediate tumour progression and poor prognosis.
Yakinthi Chrisochoidou +17 more
doaj +1 more source
SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma [PDF]
, 2018 SYSTEMS-2 is a randomised study of radiotherapy dose escalation for pain control in 112 patients with malignant pleural mesothelioma (MPM). Standard palliative (20Gy/5#) or dose escalated treatment (36Gy/6#) will be delivered using advanced radiotherapy ...
Alexander, L. +11 more
core +2 more sources
Convolutional Neural Networks for Segmentation of Malignant Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance) [PDF]
arXiv, 2023 Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma. To assess response to treatment, tumor measurements are acquired and evaluated based on a patient's longitudinal computed tomography (CT) scans. Tumor volume, however, is the more accurate metric for assessing tumor burden and response.
arxiv
Second line therapy in malignant pleural mesothelioma: a systematic review [PDF]
, 2015 After the implementation of standard first line chemotherapy with platinum and antifolates in pleural mesothelioma, patients are confronted with a need for second line treatment at relapse or progression.
Baas, Paul +3 more
core +2 more sources
, 2021 Pseudomyxoma Peritonei (PMP) and Peritoneal Mesothelioma (PM) are both rare peritoneal malignancies. Currently, affected patients may be treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy offering long-term survival or even ...
Ceelen, Wim +11 more
core +1 more source
EClinicalMedicine, 2022 Summary: Background: Currently, there is no US Food and Drug Administration approved therapy for patients with pleural mesothelioma who have relapsed following platinum-doublet based chemotherapy. Vinorelbine has demonstrated useful clinical activity in
Dean A. Fennell +16 more
doaj